IASLC WCLC

IASLC Meetings and Webinars

IASLC Meetings and Conference

Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of more than 8,000 lung cancer specialists from 100+ countries. IASLC members work towards developing and promoting the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer. IASLC’s mission is to enhance the understanding and education of lung cancer to scientists, members of the medical community and the public. In addition to the annual meeting, the IASLC publishes the Journal of Thoracic Oncology, a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.The IASLC World Conference on Lung Cancer (WCLC) is the largest international gathering in the field of lung cancer and thoracic oncology. With a stellar scientific program and well known faculty, WCLC highlights the most advanced treatments, clinical trials and studies in thoracic oncology and lung cancer.

WCLC2026

I acknowledge that my data including name, job title, organization, city/country and email address may be shared with each supporter whose virtual symposium I may attend during the Conference so that they may send me marketing communications and further information.

I acknowledge that my data including name, job title, organization, city/country and email address may be shared with each exhibitor whose virtual exhibit listing I may visit during the Conference so that they may send me marketing communications and further information.IASLC follows the European Union’s General Data Protection Regulation (GDPR) for the collection, use, disclosure, and transfer of data. IASLC would like to support exhibitors and supporters by providing nominative data including your full name and email address if you agree.If you prefer not to share your information, please click "Continue".

OA14. The Breakthrough Immunotherapy for Advanced NSCLC

Information

Presentation(s) in this Session

Chair

Chair

OA14.01. Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pembrolizumab as First-Line Treatment for PD-L1-Positive NSCLC

OA14.02. Pumitamig (PD-L1 x VEGF-A bsAb) + Elfetabart Drozuntecan (Elfe-D, B7H3 ADC) in Patients with Advanced/Metastatic Lung Cancer (NSCLC or SCLC)

OA14.03. Clinical Outcomes of the Phase III Lonestar Trial: Local Consolidation Therapy After Nivolumab Plus Ipilimumab in NSCLC

OA14.04. RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

OA14.05. Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR-Mutated NSCLC (HARMONi): Updated Overall Survival Analysis

OA14.06. Discussant

Q&A

Join the event!